NCT00031655View on ClinicalTrials.gov

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

August 31, 2006

Study Completion Date

November 30, 2012

Conditions
Adult Acute Lymphoblastic Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic Leukemia
Interventions
PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

Undergo nonmyeloablative allogeneic PBSCT

BIOLOGICAL

donor lymphocytes

Given IV

DRUG

cyclosporine

Given PO

RADIATION

total-body irradiation

Undergo TBI

DRUG

fludarabine phosphate

Given IV

DRUG

mycophenolate mofetil

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

peripheral blood stem cell transplantation

Undergo nonmyeloablative allogeneic PBSCT

Trial Locations (3)

98108

Veterans Affairs Puget Sound Healthcare System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

Unknown

Oregon Health and Sciences University, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

OTHER

NCT00031655 - Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission | Biotech Hunter | Biotech Hunter